Fate Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview

Fate Therapeutics

24/02/2024 01:31

* Fate Therapeutics Inc  FATE.OQ   FATE.O  is expected
to show a
fall in quarterly revenue when it reports  results on February
26 for the period ending December 31 2023
    * The San Diego California-based  company is expected to
report a
96.4% decrease in revenue to $1.594 million from $44.36 million
a year ago, according to the mean estimate from 18 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Fate Therapeutics Inc is
for a
loss of 52 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 13
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fate
Therapeutics
Inc is $5.50​, below​ its last closing price of $6.96. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -0.56       -0.57      -0.46     Beat    19.3
 Jun. 30 2023  -0.58       -0.59      -0.54     Beat    8.2
 Mar. 31 2023  -0.64       -0.62      -0.19     Beat    69.5​
 Dec. 31 2022  -0.85       -0.86      -0.58     Beat    32.7
 ​​Sep.        -0.87       -0.89      -0.86     Beat    3.7
 30 2022                                                
 Jun. 30 2022  -0.81       -0.83      -0.79     Beat    4.4​
 Mar. 31 2022  -0.77       -0.77      -0.68     Beat    11.1
 Dec. 31 2021  -0.65       -0.67      -0.72     Missed  -8
 This summary was machine generated February 24 at 01:31 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)